News

Employee Profile: Helena Silva Cascales

GeneMate

New guidelines for hereditary breast cancer

Editorial

Monogenic vs Polygenic Inheritance

Types of inheritance, terms, and genetic testing

Editorial

Is blood cancer hereditary?

News

Finally Kristina was able to get tested

After having lost her mom and maternal grandmother to breast cancer, Kristina wondered about her hereditary risk. Kristina got tested with GeneMate.

News

iCellate Medical expands its accredited lab

iCellate has recently finalized the expansion of its lab for the accredited service GeneMate®. GeneMate® is a service that is used to analyze an…

News

iCellate Medical secures 20 MSEK in new funding

iCellate Medical has closed a successful round of financing, raising 20 MSEK from a combination of existing and new investors.

News

iCellate launches collaboration with football player Olivia Schough

Cancer diagnostics company iCellate Medical AB announces collaboration with football star Olivia Schough. Olivia shares her story of hereditary cancer…

News

Project ELEVATE initiates clinical trial for development of novel cancer diagnostics

February 10, 2022. Elthera AG, iCellate Medical AB, Targos Molecular Pathology GmbH and Prof. Dr. Susanne Sebens at the Institute of Experimental…

GeneMate

Which genetic variants cause disease?

Changes in our DNA occur all of the time. Many are harmless, while others cause disease.

News

iCellate Expands Headquarters

Employee Profile: André Nobre

[Translate to English:]

GeneMate

Calculate your risk

What is the likelihood that you carry a pathogenic variant?

Employee Profile: Iohn Ryott

GeneMate

Mapping your family cancer history

The importance of family cancer history and how to map it

Employee Profile: Sabina Botic

Employee Profile: Emelie Berglund

GeneMate

Hereditary stomach cancer

Stomach cancer is the fifth most common cancer in the world, and 10-20% is hereditary

News

GeneMate® now a part of global rare disease database and resource Orphanet

Increased visibility of hereditary cancer risk can lead to increased opportunities for cancer prevention and early detection

News

Job Opening: Clinical Molecular Geneticist

Come join us!

GeneMate

What to expect from your GeneMate® test

GeneMate

Behind the scenes of GeneMate®

GeneMate

The importance of informing family members of a positive result

All first-degree relatives of a carrier have a 50% risk of themselves being a carrier

GeneMate

Hereditary melanoma

Melanoma is the most rapidly increasing cancer in Sweden and 10-15% of all cases are hereditary

GeneMate

Which genes does GeneMate® test and why?

Our clinically actionable selection of genes gives you a better shot at prevention.

GeneMate

Hereditary prostate cancer

1 in 5 Swedish men will be diagnosed with prostate cancer. Guidelines for the identification of hereditary prostate cancer are now expanded.

GeneMate

Hereditary cancer: 97% of all carriers remain unidentified

Family history-based testing identifies some, misses many

GeneMate

Polyposis syndromes

Polyposis' cause, associated cancer types, and risk-reducing measures

News

iCellate’s lab receives ISO 15189 certification by Swedac

iCellate is the only Swedish company that holds an ISO 15189 certification within cancer diagnostics.

GeneMate

Hereditary ovarian cancer

15-20% of all ovarian cancer is hereditary

GeneMate

Lynch Syndrome

Lynch syndrom is caused by hereditary pathogenic variants and increases the risk of several different cancer types

GeneMate

Things to consider prior to genetic testing

Editorial

This is our mission

GeneMate

Hereditary breast cancer

15-20% of all breast cancer is hereditary

 

Editorial

R&D Update: project ELEVATE

GeneMate

Hereditary colorectal cancer

One third of all colorectal cancer is hereditary

News

Elthera-led consortium initiates development of novel cancer diagnostics and therapeutics

News

iCellate has been selected to participate in Novartis' Techcare program

News

Study presented at KICancer - StratCan

Research

The early detection of cancer study (ICELLATE1) – published in the Journal of Integrative Oncology

Research

Groundbreaking pan-cancer screening study published

News

iCellate enters partnership with RCC Stockholm-Gotland

News

iCellate Medical closes 15 million SEK second round of funding

News

iCellate Medical receives orders for clinical CTC services from major institutions and adds valuable sequencing competence to the company